BRPI0415767A - antagonistas de receptor de ccr-3 - Google Patents

antagonistas de receptor de ccr-3

Info

Publication number
BRPI0415767A
BRPI0415767A BRPI0415767-2A BRPI0415767A BRPI0415767A BR PI0415767 A BRPI0415767 A BR PI0415767A BR PI0415767 A BRPI0415767 A BR PI0415767A BR PI0415767 A BRPI0415767 A BR PI0415767A
Authority
BR
Brazil
Prior art keywords
ccr
receptor antagonists
compounds
nep
useful
Prior art date
Application number
BRPI0415767-2A
Other languages
English (en)
Inventor
Leyi Gong
Robert Stephen Wilhelm
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0415767A publication Critical patent/BRPI0415767A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"ANTAGONISTAS DE RECEPTOR DE CCR-3". A presente invenção refere-se a compostos de Fórmula (I): onde R¬ 2¬, R¬ 3¬, R¬ 4¬, R¬ 9¬, Ar, U~ c~, X, Y, Q, n e p são como definidos no relatório descritivo. Os compostos são úteis como antagonistas de receptor de CCR-3 e, portanto, poderão ser usados para tratamento de doenças mediadas por CCR-3.
BRPI0415767-2A 2003-10-24 2004-10-14 antagonistas de receptor de ccr-3 BRPI0415767A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51429603P 2003-10-24 2003-10-24
PCT/EP2004/011545 WO2005040129A2 (en) 2003-10-24 2004-10-14 Ccr3 receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0415767A true BRPI0415767A (pt) 2006-12-26

Family

ID=34520190

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415767-2A BRPI0415767A (pt) 2003-10-24 2004-10-14 antagonistas de receptor de ccr-3

Country Status (14)

Country Link
US (1) US20050090504A1 (pt)
EP (1) EP1680408A2 (pt)
JP (1) JP2007509095A (pt)
KR (1) KR20060061393A (pt)
CN (1) CN1871222A (pt)
AR (1) AR046340A1 (pt)
AU (1) AU2004283842A1 (pt)
BR (1) BRPI0415767A (pt)
CA (1) CA2543419A1 (pt)
MX (1) MXPA06004304A (pt)
RU (1) RU2006117631A (pt)
SG (1) SG131946A1 (pt)
TW (1) TW200522957A (pt)
WO (1) WO2005040129A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101563319B (zh) 2006-12-19 2012-09-05 弗·哈夫曼-拉罗切有限公司 杂芳基吡咯烷基和哌啶基甲酮衍生物
BRPI0914160A2 (pt) * 2008-06-18 2019-09-24 Hoffmann La Roche aril cetona como mri
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US8445674B2 (en) * 2009-10-21 2013-05-21 Hoffmann-La Roche Inc Heterocyclyl compounds
CN102050809B (zh) * 2009-11-03 2014-12-17 中国医学科学院药物研究所 拮抗cklf1/ccr4相互作用的3-哌嗪基香豆素衍生物
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2334266A1 (de) * 1972-07-07 1974-01-31 Hisamitsu Pharmaceutical Co Pyrido eckige klammer auf 2,3-d eckige klammer zu pyrimidin-2,4 (1h, 3h)-dione
US3922275A (en) * 1972-11-09 1975-11-25 Hisamitsu Pharmaceutical Co Pyrido{8 2,3-D{9 {0 pyrimidine-2,4(1H,3H)-diones
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
EP0040793B1 (en) * 1980-05-22 1985-08-28 Masayuki Ishikawa Novel quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof
US4695575A (en) * 1984-11-13 1987-09-22 Janssen Pharmaceutica, N.V. 4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines
US4839374A (en) * 1984-01-09 1989-06-13 Janssen Pharmaceutica, N.V. 4-((Bicyclic heterocyclyl)-methyl and -hetero)-piperidines
JPH0615529B2 (ja) * 1985-04-01 1994-03-02 エーザイ株式会社 新規ピペリジン誘導体
US5143923B1 (en) * 1991-04-29 1993-11-02 Hoechst-Roussel Pharmaceuticals Incorporated Benzoisothiazole-and benzisoxazole-3-carboxamides
US6126964A (en) * 1996-01-04 2000-10-03 Mirus Corporation Process of making a compound by forming a polymer from a template drug
WO1998005332A1 (en) * 1996-08-01 1998-02-12 Isis Pharmaceuticals, Inc. Novel heterocycle compositions
FR2753970B1 (fr) * 1996-10-01 1998-10-30 Synthelabo Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
US6084098A (en) * 1999-02-26 2000-07-04 Neurogen Corporation Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands
US6284759B1 (en) * 1998-09-30 2001-09-04 Neurogen Corporation 2-piperazinoalkylaminobenzo-azole derivatives: dopamine receptor subtype specific ligands
EP1117663A2 (en) * 1998-09-30 2001-07-25 Neurogen Corporation 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands
BR9915403A (pt) * 1998-11-17 2001-08-14 Hoffmann La Roche Antagonistas receptores iii de 4-aroil-piperidin-ccr-3
CA2351631A1 (en) * 1998-11-20 2000-06-02 F. Hoffmann-La Roche Ag Piperidine quaternary salts-ccr-3 receptor antagonists
JP3593037B2 (ja) * 1998-11-20 2004-11-24 エフ．ホフマン−ラ ロシュ アーゲー ピロリジン誘導体ｃｃｒ−３受容体アンタゴニスト
TR200102800T2 (tr) * 1999-03-26 2002-01-21 Astrazeneca Ab Yeni bileşikler.
WO2000076967A1 (en) * 1999-06-14 2000-12-21 Neurogen Corporation Benzylpiperazinyl-indolinylethanones
US6476041B1 (en) * 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
ES2291293T3 (es) * 2000-02-29 2008-03-01 Mitsubishi Pharma Corporation Nuevos derivados amida ciclicos.
AU2001292276A1 (en) * 2000-09-27 2002-04-08 Toray Industries, Inc. Nitrogen-containing compounds and ccr3 inhibitors containing the same as the active ingredient
MXPA03005581A (es) * 2000-12-19 2003-10-06 Hoffmann La Roche Pirrolidinas substituidas como antagonistas del receptor ccr-3.
GB0203299D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel compounds
JPWO2004011430A1 (ja) * 2002-07-25 2005-11-24 アステラス製薬株式会社 ナトリウムチャネル阻害剤

Also Published As

Publication number Publication date
WO2005040129A2 (en) 2005-05-06
EP1680408A2 (en) 2006-07-19
US20050090504A1 (en) 2005-04-28
JP2007509095A (ja) 2007-04-12
KR20060061393A (ko) 2006-06-07
SG131946A1 (en) 2007-05-28
MXPA06004304A (es) 2006-06-05
WO2005040129A3 (en) 2005-06-23
RU2006117631A (ru) 2007-12-10
CA2543419A1 (en) 2005-05-06
TW200522957A (en) 2005-07-16
CN1871222A (zh) 2006-11-29
AR046340A1 (es) 2005-12-07
AU2004283842A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
BRPI0507462A (pt) compostos de quinolina substituìdos
DK1501507T3 (da) Tetrahydropyranyl-cyclopentyl-tertrahydropyridopyrindin-modulatorer af kemokin-receptor-aktivitet
SE0102616D0 (sv) Novel compounds
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
DK1776349T3 (da) 2-amino-puinazolin derivater anvendelige som inhibitorer af beta-sekretase (BACE)
BR0316375A (pt) Diazinopirimidinas
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
EA200800172A1 (ru) 2,4-диаминопиримидины как ингибиторы aurora
BRPI0412851A (pt) benzamidazóis de n-metila-substituìdos
MX2009006921A (es) Derivados azaespiro.
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
WO2007047646A3 (en) Substituted dihydro-isoindolones useful in treating kinase disorders
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
BRPI0407913A (pt) antagonistas receptores de ccr-3
BRPI0416030A (pt) pirido-7-pirimidin-7-onas substituìdas com hidroxialquila
BRPI0517032A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e utilização desses compostos
EA200970192A1 (ru) Производные 5,6-бисарил-2-пиридин-карбоксамида, их получение и их применение в терапии в качестве антагонистов рецепторов уротензина ii
ATE418548T1 (de) Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten
BRPI0409580A (pt) compostos de quinazolina
EA200700550A1 (ru) Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
BRPI0415767A (pt) antagonistas de receptor de ccr-3
SE0403085D0 (sv) Novel componds
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
MXPA04004981A (es) Derivados de piperazina para uso como antagonistas del receptor ccr-3 en tratamiento de asma.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]